The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2 - PubMed (original) (raw)

The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2

Jinfeng Ren et al. Biomaterials. 2012 Apr.

Abstract

In this study, a dual-targeting drug delivery system based on PEGylated oxidized multi-walled carbon nanotubes (O-MWNTs) modified with angiopep-2 (O-MWNTs-PEG-ANG) was successfully developed for treatment of brain glioma. O-MWNTs can not only distribute in brains but also accumulate in tumors, and have ultrahigh surface area with remarkably high loading anticancer drug of doxorubicin (DOX), which was selected as drug carrier. Angiopep-2 can specifically combine to the low-density lipoprotein receptor-related protein (LRP) receptor overexpressed on the blood-brain barrier (BBB) and glioma cells, which was selected as targeting ligand. The cooperative dual-targeting to brain glioma by O-MWNTs-PEG-ANG was evaluated by intracellular tracking in vitro and fluorescence imaging in vivo, which demonstrated that the combination of O-MWNTs-PEG and angiopep-2 constituted an ideal dual-targeting drug delivery system. The anti-glioma effect of DOX-loaded O-MWNTs-PEG-ANG (DOX-O-MWNTs-PEG-ANG) was assessed by C6 cytotoxicity and median survival time of glioma bearing mice, which showed a better anti-glioma effect than DOX. The biological safety of O-MWNTs-PEG-ANG was evaluated by BCEC and C6 cytotoxicity, hematology analysis and CD68 immunohistochemical analysis, which proved O-MWNTs-PEG-ANG was good biocompatibility and low toxicity. The biological safety of DOX-O-MWNTs-PEG-ANG was evaluated by histopathological analysis, which suggested a lower cardiac toxicity than DOX. In conclusion, O-MWNTs-PEG-ANG is a promising dual-targeting carrier to deliver DOX for the treatment of brain tumor.

PubMed Disclaimer

Cited by

Core-shell nanocarriers with high paclitaxel loading for passive and active targeting.
Jin Z, Lv Y, Cao H, Yao J, Zhou J, He W, Yin L. Jin Z, et al. Sci Rep. 2016 Jun 9;6:27559. doi: 10.1038/srep27559. Sci Rep. 2016. PMID: 27278751 Free PMC article.
Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration.
Zhang X, He T, Chai Z, Samulski RJ, Li C. Zhang X, et al. Biomaterials. 2018 Sep;176:71-83. doi: 10.1016/j.biomaterials.2018.05.041. Epub 2018 May 26. Biomaterials. 2018. PMID: 29860139 Free PMC article.
Carbon nanotubes: an emerging drug carrier for targeting cancer cells.
Rastogi V, Yadav P, Bhattacharya SS, Mishra AK, Verma N, Verma A, Pandit JK. Rastogi V, et al. J Drug Deliv. 2014;2014:670815. doi: 10.1155/2014/670815. Epub 2014 Apr 24. J Drug Deliv. 2014. PMID: 24872894 Free PMC article. Review.
Application of Carbon Nanomaterials to Enhancing Tumor Immunotherapy: Current Advances and Prospects.
Li Y, Xu Z, Qi Z, Huang X, Li M, Liu S, Yan Y, Gao M. Li Y, et al. Int J Nanomedicine. 2024 Oct 26;19:10899-10915. doi: 10.2147/IJN.S480799. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39479174 Free PMC article. Review.
Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.
Zhang F, Xu CL, Liu CM. Zhang F, et al. Drug Des Devel Ther. 2015 Apr 9;9:2089-100. doi: 10.2147/DDDT.S79592. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25926719 Free PMC article. Review.

The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2 - PubMed (original) (raw)